Jasper Therapeutics Enters Research Collaboration with Avrobio for Ex Vivo Gene Therapy

Jasper Therapeutics said it entered a non-exclusive research collaboration with Avrobio to evaluate the use of JSP191, Jasper’s anti-CD117 monoclonal antibody, as a targeted conditioning agent option for patients with Fabry disease and/or Gaucher disease type 1 who are being treated with one of Avrobio’s experimental ex vivo lentiviral gene therapies.

Photo: Bill Lis, executive chairman and CEO of Jasper Therapeutics

JSP191 is a humanized monoclonal antibody in clinical development as a conditioning agent that blocks stem cell factor receptor signaling leading to clearance of hematopoietic stem cells from bone marrow, creating an empty space for donor or genetically modified transplanted stem cells to engraft.

To date, JSP191 has been evaluated in more than 90 healthy volunteers and patients. Two clinical trials for myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) and severe combined immunodeficiency (SCID) are currently enrolling. Enrollment in five additional studies are planned in patients with severe autoimmune disease, Fanconi anemia, sickle cell disease, chronic granulomatous disease, and GATA2 MDS who are undergoing hematopoietic cell transplantation.

“We believe the use of JSP191 in Avrobio’s Fabry disease and/or Gaucher disease type 1 investigational gene therapy programs offers patients and doctors a compelling new option when it comes to matching a patient’s disease with a conditioning agent meeting their therapeutic goals and requirements,” said Bill Lis, executive chairman and CEO of Jasper Therapeutics.

Each company will retain commercial rights to their respective technologies.

Author: Rare Daily Staff